| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $1.35B | +67.6% |
| Cost of Revenue | $2.61B | +50.8% |
| R&D Expense | $1.21B | +3.0% |
| SG&A Expense | $1.03B | +14.8% |
| Operating Income | -$3.50B | -15.9% |
| Pre-tax Income | -$2.70B | +0.5% |
| Income Tax | -$2.3M | -294.6% |
| Net Income | -$2.70B | +0.6% |
| EPS (Basic) | -$11.81 |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $997.8M | -37.9% |
| Short-term Investments | $631.1M | -74.0% |
| Accounts Receivable | $177.2M | +58.1% |
| Inventory | $1.11B | +172.1% |
| Current Assets | $3.30B | -32.3% |
| Total Assets | $8.39B | -13.1% |
| Current Liabilities | $2.64B | +126.2% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$2.93B | -45.2% |
| Capital Expenditures | $868.2M | -1.8% |
| Investing Cash Flow | $1.48B | +214.2% |
| Financing Cash Flow | $887.3M | -75.0% |
| Free Cash Flow | -$3.80B | -30.9% |
| -844.8% |
| EPS (Diluted) | -$12.09 | -867.2% |
| Long-term Debt |
| $2.05B |
| +2.2% |
| Total Liabilities | $5.39B | +20.4% |
| Stockholders' Equity | $717.3M | -81.5% |